Targeted protein degradation (TPD) is an emerging protein degradation technology in recent decades that utilizes the cell’s own protein clearance mechanisms, such as lysosomal degradation and proteasomal degradation, to degrade target […]
Immunotherapy, which uses immune pathways to treat cancer, is rapidly becoming an accepted cancer treatment after surgery, chemotherapy and radiation. Checkpoint blocking using monoclonal antibodies against cytotoxic T lymphocyte-associated protein […]
In 2001, the FDA approved Imatinib, the first drug to be developed by targeting a specific protein kinase and the first molecularly targeted drug to fight cancer. It was considered […]
MYC protein is an inherently disordered protein, which lacks a hydrophobic pocket or groove suitable for binding small molecule compounds. Currently, no small molecule compounds that can bind MYC have […]
Facing the Coronavirus with continuous mutations, researchers are working hard to develop effective and broad-spectrum anti-Coronavirus drugs and vaccines. At the end of 2021, the small molecule oral drug was […]
The Coronavirus outbreak has posed a great threat to human health. Facing the continuous mutation of Coronavirus, researchers are working hard to develop effective and broad-spectrum anti-COVID-19 drugs as well […]
Abstract Immunotherapy has become an indispensable part of cancer treatment. A pivotal phagocytosis checkpoint, named cluster of differentiation 47 (CD47), which functions as a ‘don’t eat me’ signal to protect […]
Compared with biological drugs, small molecule drugs have greater advantages in R&D cost and process maturity, and they are still the main battlefield for drug research and development. According to […]
In the past 2018, the global drug sales champion was still the macromolecular monoclonal antibody Humira (just short of $20 billion). The Top2 variety is a small molecular drug, but […]